Pick · 11.0% · large · Health Care · last 113.90
Entry 108.00–114.00 · Stop 100.00 · Target 136.00
Thesis (long, position, conviction 65)
Bull: Halozyme is compounding both revenue and profitability at a rapid clip: Q2'26 revenue grew 47.7% YoY to $481.0M, operating income grew 42.1% to $287.7M (~60% operating margin), and diluted EPS rose to $1.90 from $1.33 (F-HALO-4, F-HALO-5, F-HALO-6, F-HALO-7). The stock is confirming this fundamental strength technically: it closed at $113.90, just 1.15% off its 52-week high, above its 20/50/200-day moving averages, and has returned 51.95% over three months versus SPY's much smaller move (45.87% relative strength) (F-HALO-1, F-HALO-2, F-HALO-3). Sell-side sentiment is uniformly positive — 13 of 16 covering analysts rate it strong buy/buy with zero sells (F-HALO-11). Management is proactively managing its balance sheet: the $1.5B convert due 2033 was priced with an initial conversion price of ~$139.84 (23% above spot), and roughly $652.5M of proceeds are earmarked to retire nearer-dated 2027/2028 converts while ~$187.5M funded capped calls to blunt future dilution (F-HALO-8, F-HALO-9, F-HALO-10) — this is debt-maturity extension and dilution management, not distress financing, and it was done from a position of strength with cash on the balance sheet growing.
Bear: The stock has already run up over 50% in three months and sits just below its all-time closing high with RSI14 at 64, leaving less margin of safety and raising mean-reversion risk if Q3 results merely meet rather than beat the $2.397 EPS / ~$499.4M revenue consensus (brief catalyst, no confirmed date). The new $1.5B convertible adds ~$1.5B of principal obligations and, above the $139.84 conversion price, a path to per-share dilution or cash settlement pressure if the stock keeps climbing (F-HALO-9, red flag on future repayment obligations and dilution). The brief provides no explicit valuation multiple (P/E, FCF yield) or forward guidance, so the "growth at a reasonable price" thesis rests on inferred metrics rather than disclosed ones, and the Q3 earnings date itself is only an estimate, not confirmed by the company (data gap).
Valuation: The brief has no directly stated P/E, FCF yield, or forward guidance, so this is an inferred view: annualizing the Q2'26 diluted EPS of $1.90 (F-HALO-7) suggests a trailing run-rate near $7.60/share, putting the $113.90 price at roughly 15x trailing earnings against 47.7% revenue growth and ~60% operating margins (F-HALO-4, F-HALO-5) — a growth/quality profile that would typically command a premium multiple, making the current price look reasonable rather than stretched, though this is an estimate rather than a fact from the brief. The convert's conversion price of ~$139.84 also implicitly caps near-term dilution risk about 23% above the current price.
Catalysts
2026-11-02: Estimated Q3 2026 earnings release; consensus EPS $2.397 and revenue ~$499.4M — a beat/raise would extend the uptrend, a miss risks a sharp pullback given the recent 52% three-month run.
undated: Execution of the $652.5M tender/repurchase of 2027 and 2028 convertible notes using proceeds from the new 2033 convert, which reduces near-term refinancing risk and clarifies pro forma share count.
Facts
F-HALO-1: HALO closed at $113.90 on 2026-09-25, 1.15% below its 52-week closing high of $115.22. (as of 2026-09-25)[E29]
F-HALO-2: The stock returned 51.95% over the three months ended 2026-09-25; its reported three-month relative strength versus SPY was 45.87%. (as of 2026-09-25)[E29]
F-HALO-3: On 2026-09-25, the closing price of $113.90 was above the 20-day ($109.65), 50-day ($99.74) and 200-day ($77.13) moving averages. (as of 2026-09-25)[E29]
F-HALO-4: Revenue for the quarter ended 2026-06-30 was $481.0 million, up 47.7% from $325.7 million in the quarter ended 2025-06-30. (as of 2026-06-30)[E30]
F-HALO-5: Operating income for the quarter ended 2026-06-30 was $287.7 million, up 42.1% from $202.4 million a year earlier. (as of 2026-06-30)[E30]
F-HALO-6: Net income for the quarter ended 2026-06-30 was $229.9 million, compared with $165.2 million for the quarter ended 2025-06-30. (as of 2026-06-30)[E30]
F-HALO-7: Diluted EPS for the quarter ended 2026-06-30 was $1.90, compared with $1.33 for the quarter ended 2025-06-30. (as of 2026-06-30)[E30]
F-HALO-8: Halozyme completed a $1.5 billion offering of 1.50% convertible senior notes due 2033 on 2026-09-22 and received approximately $1.471 billion in net proceeds. (as of 2026-09-22)[E62]source
F-HALO-9: The notes’ initial conversion price is approximately $139.84 per share; Halozyme may settle conversions in cash and, if applicable, shares, at its election. (as of 2026-09-22)[E70]source
F-HALO-10: Halozyme said it used approximately $187.5 million of offering proceeds for capped-call transactions and expected to spend approximately $652.5 million, including accrued interest, to repurchase portions of its 2027 and 2028 convertible notes. (as of 2026-09-22)[E70]source
F-HALO-11: For September 2026, analyst recommendations included 3 strong buys, 10 buys and 3 holds, with no sells or strong sells. (as of 2026-09-01)[E67]
Critic
O5 (major): Increasing HALO to 11% after its sharp run is not adequately reconciled with the newly issued convertible debt. Open: HALO's rise to 11% still lacks reconciliation with its newly issued convertible debt; strategist has not yet responded.
What would change the view
A daily close below $100 (stop level / near 50-day MA)
Q3 2026 diluted EPS reported below $2.00, well under the $2.397 consensus
Confirmed guidance cut or negative commentary tied to the newly issued 2033 converts
A shift in analyst ratings toward holds/sells from the current 13 buy-equivalent, 3 hold split
Data quality
Quality score 100/100.
Gap: The quote block is timestamped 2026-09-27, after the supplied current date of 2026-09-25, so the dated daily close series was used instead.
Gap: The supplied data does not establish whether the estimated 2026-11-02 earnings date has been confirmed by the company.
Red flag: The $1.5 billion unsecured convertible notes create future repayment obligations and potential share dilution; the initial conversion price is approximately $139.84 per share. (E62, E70)